［1］Kerr JF,Wyllie AH,Currie AR.Apoptosis:A basic biological phenomenon with wide-ranging implications in tissue kinetics［J］.Br J Cancer,1972,26(4):239-257.
［2］Degterev A,Huang Z,Boyce M,et al.Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury［J］.Nat Chem Biol,2005,1(2):112-119.
［3］Su Z,Yang Z,Xie L,et al.Cancer therapy in the necroptosis era［J］.Cell Death Differ,2016,23(5):748-756.
［4］Vanden Berghe T,Linkermann A,Jouan-Lanhouet S,et al.Regulated necrosis:The expanding network of non-apoptotic cell death pathways［J］.Nat Rev Mol Cell Biol,2014,15(2):135-147.
［5］Pasparakis M,Vandenabeele P.Necroptosis and its role in inflammation［J］.Nature,2015,517(7534):311-320.
［6］Feng S,Yang Y,Mei Y,et al.Cleavage of RIP3 inactivates its caspase-independent apoptosis pathway by removal of kinase domain［J］.Cell Signal,2007,19(10):2056-2067.
［7］Vercammen D,Beyaert R,Denecker G,et al.Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor［J］.J Exp Med,1998,187(9):1477-1485.
［8］Chen YL.The regulatory mechanism of nerroptosis and its molecular targeted agents related research progress［J］.Zhejiang Journal of Integrated Traditional Chinese and Western Medicine,2017,27(5):453-455.［陈俞乐.坏死性凋亡调节机制及其分子靶向药物相关研究进展［J］.浙江中西医结合杂志,2017,27(5):453-455.］
［9］Tummers B,Green DR.Caspase-8:Regulating life and death［J］.Immunol Rev,2017,277(1):76-89.
［10］Seifert L,Werba G,Tiwari S,et al.The necrosome promotes pancreatic oncogenesis via CXCL1 and mincle-induced immune suppression［J］.Nature,2016,532(7598):245-249.
［11］Moquin DM,McQuade T,Chan FK.CYLD deubiquitinates RIP1 in the TNFα-induced necrosome to facilitate kinase activation and programmed necrosis［J］.PLoS One,2013,8(10):e76841.
［12］Moujalled DM,Cook WD,Okamoto T,et al.TNF can activate RIPK3 and cause programmed necrosis in the absence of RIPK1［J］.Cell Death Dis,2013,4:e465.
［13］Wu CL,Xie NN,Zhou SA,et al.The molecular mechanisms of necroptosis and its role in inflammation［J］.Chinese Journal of Cell Biology,2016,38(1):7-16.［吴晨露,谢南南,周伸奥,等.程序性细胞坏死的分子机制及其在炎症中的作用［J］.中国细胞生物学学报,2016,38(1):7-16.］
［14］Brault M,Oberst A.Controlled detonation:Evolution of necroptosis in pathogen defense［J］.Immunol Cell Biol,2017,95(2):131-136.
［15］Wang NN,Wang DW,Liang YX.The relationship between Necroptosis and disease［J］.Pharmaceutical Biotechnology,2017,24(3):275-278.［王楠楠,王德伟,梁映霞.Necroptosis与疾病的关系［J］.药物生物技术,2017,24(3):275-278.］
［16］Cai Z,Jitkaew S,Zhao J,et al.Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis［J］.Nat Cell Biol,2014,16(1):55-65.
［17］Wang H,Sun L,Su L,et al.Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3［J］.Mol Cell,2014,54(1):133-146.
［18］Yoon S,Kovalenko A,Bogdanov K,et al.MLKL,the protein that mediates necroptosis,also regulates endosomal trafficking and extracellular vesicle generation［J］.Immunity,2017,47(1):51-65.
［19］Jing L,Song F,Liu Z,et al.MLKL-PITPα signaling-mediated necroptosis contributes to cisplatin-triggered cell death in lung cancer A549 cells［J］.Cancer Lett,2018,414:136-146.
［20］Gong YN,Guy C,Olauson H,et al.ESCRT-Ⅲ acts downstream of MLKL to regulate necroptotic cell death and its consequences［J］.Cell,2017,169(2):286-300.
［21］Omoto S,Guo H,Talekar GR,et al.Suppression of RIP3-dependent necroptosis by human cytomegalovirus［J］.J Biol Chem,2015,290(18):11635-11648.
［22］Geserick P,Wang J,Schilling R,et al.Absence of RIPK3 predicts necroptosis resistance in malignant melanoma［J］.Cell Death Dis,2015,6:e1884.
［23］Chen X,Li W,Ren J,et al.Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death［J］.Cell Res,2014,24(1):105-121.
［24］Blohberger J,Kunz L,Einwang D,et al.Readthrough acetylcholinesterase (AChE-R) and regulated necrosis:Pharmacological targets for the regulation of ovarian functions［J］?Cell Death Dis,2015,6:e1685.
［25］Weinlich R,Oberst A,Beere HM,et al.Necroptosis in development,inflammation and disease［J］.Nat Rev Mol Cell Biol,2017,18(2):127-136.
［26］Wang RA,Li ZS,Yan QG,et al.Resistance to apoptosis should not be taken as a hallmark of cancer［J］.Chin J Cancer,2014,33(2):47-50.
［27］New J,Arnold L,Ananth M,et al.Secretory autophagy in cancer-associated fibroblasts promotes head and neck cancer progression and offers a novel therapeutic target［J］.Cancer Res,2017,77(23):6679-6691.
［28］Wang WC,Shi LH,Yin ZF.Progress in survival regulatory mechanism of circulating tumor cells and their targeted therapeutic strategies［J］.Tumor,2017,37(2):188-194.［王文超,施乐华,殷正丰.循环肿瘤细胞存活调节机制及其靶向治疗策略的研究进展［J］.肿瘤,2017,37(2):188-194.］
［29］Raposo TP,Beirao BC,Pang LY,et al.Inflammation and cancer:Till death tears them apart［J］.Vet J,2015,205(2):161-174.
［30］Hanggi K,Vasilikos L,Valls AF,et al.RIPK1/RIPK3 promotes vascular permeability to allow tumor cell extravasation independent of its necroptotic function［J］.Cell Death Dis,2017,8(2):e2588.
［31］Tafani M,Sansone L,Limana F,et al.The interplay of reactive oxygen species,hypoxia,inflammation and sirtuins in cancer initiation and progression［J］.Oxid Med Cell Longev,2016,2016(1):1-18.
［32］Strilic B,Yang L,Albarran-Juarez J,et al.Tumour-cell-induced endothelial cell necroptosis via death receptor 6 promotes metastasis［J］.Nature,2016,536(7615):215-218.
［33］Liu X,Zhou M,Mei L,et al.Key roles of necroptotic factors in promoting tumor growth［J］.Oncotarget,2016,7(16):22219-22233.
［34］Schmidt SV,Seibert S,Walch-Rückheim B,et al.RIPK3 expression in cervical cancer cells is required for PolyIC-induced necroptosis,IL-1α release and efficient paracrine dendritic cell activation［J］.Oncotarget,2015,6(11):8635-8647.
［35］Xu Y,Ma HB,Fang YL,et al.Cisplatin-induced necroptosis in TNFα dependent and independent pathways［J］.Cell Signal,2017,31:112-123.
［36］Grassilli E,Ianzano L,Bonomo S,et al.GSK3A is redundant with GSK3B in modulating drug resistance and chemotherapy-induced necroptosis［J］.PLoS One,2014,9(7):e100947.
［37］Oliver Metzig M,Fuchs D,Tagscherer KE,et al.Inhibition of caspases primes colon cancer cells for 5-fluorouracil-induced TNF-α-dependent necroptosis driven by RIP1 kinase and NF-κB［J］.Oncogene,2016,35(26):3399-3409.
［38］Safferthal C,Rohde K,Fulda S.Therapeutic targeting of necroptosis by Smac mimetic bypasses apoptosis resistance in acute myeloid leukemia cells［J］.Oncogene,2017,36(11):1487-1502.
［39］Aaes TL,Kaczmarek A,Delvaeye T,et al.Vaccination with necroptotic cancer cells induces efficient anti-tumor immunity［J］.Cell Rep,2016,15(2):274-287.
［40］Philipp S,Sosna J,Adam D.Cancer and necroptosis:Friend or foe［J］?Cell Mol Life Sci,2016,73:2183-2193.
［41］Lu B,Gong X,Wang ZQ,et al.Shikonin induces glioma cell necroptosis in vitro by ROS overproduction and promoting RIP1/RIP3 necrosome formation［J］.Acta Pharmacol Sin,2017,38(11):1543-1553.
［42］Zhou Z,Lu B,Wang C,et al.RIP1 and RIP3 contribute to shikonin-induced DNA double-strand breaks in glioma cells via increase of intracellular reactive oxygen species［J］.Cancer Lett,2017,390:77-90.
［43］Zhang X,Kitatani K,Toyoshima M,et al.Ceramide nanoliposomes as a MLKL-dependent,necroptosis-inducing,chemotherapeutic reagent in ovarian cancer［J］.Mol Cancer Ther,2018,17(1):50-59.
［44］Moriwaki K,Bertin J,Gough PJ,et al.Differential roles of RIPK1 and RIPK3 in TNF-induced necroptosis and chemotherapeutic agent-induced cell death［J］.Cell Death Dis,2015,6:e1636.
［45］Koo GB,Morgan MJ,Lee DG,et al.Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics［J］.Cell Res,2015,25(6):707-725.
［46］Yang Z,Jiang B,Wang Y,et al.2-HG inhibits necroptosis by stimulating DNMT1-dependent hypermethylation of the RIP3 Promoter［J］.Cell Rep,2017,19(9):1846-1857.
［47］Bozec D,Iuga AC,Roda G,et al.Critical function of the necroptosis adaptor RIPK3 in protecting from intestinal tumorigenesis［J］.Oncotarget,2016,7(29):46384-46400.
［48］Sun Y,Zhai L,Ma S,et al.Down-regulation of RIP3 potentiates cisplatin chemoresistance by triggering HSP90-ERK pathway mediated DNA repair in esophageal squamous cell carcinoma［J］.Cancer Lett,2018,418:97-108.
［49］Colbert LE,Fisher SB,Hardy CW,et al.Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma［J］.Cancer,2013,119(17):3148-3155.
［50］He L,Peng K,Liu Y,et al.Low expression of mixed lineage kinase domain-like protein is associated with poor prognosis in ovarian cancer patients［J］.Onco Targets Ther,2013,6:1539-1543.
［51］Li X,Guo J,Ding AP,et al.Association of mixed lineage kinase domain-like protein expression with prognosis in patients with colon cancer［J］.Technol Cancer Res Treat,2017,16(4):428-434.
［52］Ruan J,Mei L,Qian Z,et al.Mixed lineage kinase domain-like protein is a prognostic biomarker for cervical squamous cell cancer［J］.Int J Clin Exp Pathol,2015,8(11):15035-15038.